“Although more evidence is needed before changing clinical practice, these are highly promising results, suggesting that (Bavencio) could prevent patients with chemo-resistant disease from the severe toxicity of chemotherapy combinations.”
Kevin Wright
Advertisement
Articles by Kevin Wright
When compared with Nexavar, Fotivda showed improved progression-free survival, and a more manageable safety profile for patients with relapsed or refractory metastatic renal cell carcinoma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CURE
1
Lynch Syndrome: Why Upper Endoscopies and Colonoscopy Prep Save My Life
2
Top 5 Takeaways From ASCO 2026 That Patients Should Know
3
Iza-Bren Improves Survival in Metastatic Triple-Negative Breast Cancer
4
FDA Approves Cavhanza for PH-positive Chronic Myeloid Leukemia
5